Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 9 - The Real Truth

Chinese take risks on black-market Covid drugs

BEIJING: Desperate families searching for critical Covid-19 medication in China, faced with bare pharmacy shelves and an explosion of cases, are being driven into murky online marketplaces rife with price gouging and fraud.

Bangkok Post

Lisa Jarvis: Cancer vaccine hunt makes progress, finally

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

Tribune News Service

3 High-Flying Pharma Stocks to Buy Right Now

The healthcare industry is poised to grow significantly in the coming years. Moreover, as healthcare stocks tend to perform relatively well despite macro uncertainties due to inelastic demand for their products and services, high-flying pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Merck & Co (MRK) might be ideal investments…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Ebola vaccines produced lasting antibodies during trial: Studies

Studies in West Africa said the vaccines developed by Johnson & Johnson and Merck & Co appear to be safe in children.

Al Jazeera

J&J and Merck Ebola vaccines produce lasting antibodies in children and adults -studies

Ebola vaccines developed by Johnson Johnson and Merck Co produced virus-fighting antibodies and appear to be safe in children and adults, according to data from two studies published on Wednesday.

Reuters

Cancer vaccine halves risk of relapse or death using Covid jab technology

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

The Independent UK

Skin cancer vaccine trial shows promising results

Moderna and Merck team up in new study.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Researchers from Moderna and Merck just made a breakthrough with a skin cancer vaccine

Thank you, science.

Mic

Merck, Moderna detail potential skin cancer vaccine progress

Shares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study

The Independent UK

Indonesia to produce Merck's HPV vaccines to combat cervical cancer

Indonesia will produce drugmaker Merck Co's vaccines for human papillomavirus (HPV), the chief of its state-owned pharmaceutical company Bio Farma said on Tuesday, in a bid to combat HPV-linked cervical cancer in the country.

Reuters

3 Stocks Insiders Can’t Stop Buying This Month

After signs of cooling inflation, investors are hopeful that the Fed will slow its rate hikes over the coming months. With surging optimism, fundamentally strong stocks Merck (MRK), Coca-Cola (KO), and Verizon (VZ), which have seen increased insider buying, might be ideal investments now. Continue reading.

StockNews.com

Uganda ends school year early as it tries to contain growing Ebola outbreak

Since the outbreak began in September, eight children have died — and there is no approved vaccine. But doctors are hopeful that public health measures may be enough to stop the spread.

WEKU

The COVID drug under a cloud that made billions

'It's a big deal because the Australian government purchased a huge amount of that drug.'

Newcastle Herald

This Health Care Stock Is a No-Brainer Buy for Fall

Merck & Co.’s (MRK) third-quarter financials surpassed Wall Street’s expectations. The stock is trading near its 52-week high of $101.50, and its momentum is expected to continue, considering its strong fundamentals. Given the company’s solid growth, reliable dividend payments, and the resilience of its sector against the expected economic slowdown,…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Radio France Internationale

Merck charged in France over failure to inform on changes to thyroid drug

The French unit of German pharmaceuticals firm Merck has been charged with willful commercial deception for failing to inform patients of changes to a thyroid treatment that could result in serious side-effects.

Daily Mirror

Breakthrough cancer vaccine could be ready in months, say scientists

Manufacturers Moderna and Merck are testing a breakthrough cancer vaccine for patients suffering from melanoma which kills thousands of people each year in the UK

Benzinga

Amazon Halts Delivery Bots; Merck's Covid-19 Pill Didn't Reduce Risk; Samsung Profits Slip; Adidas Reviews Relationship With Kanye: Top Stories Friday, Oct. 7

Benzinga

StockNews.com

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

2 Reliable Drug Stocks to Buy and Hold for Big-Time Gains

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

Benzinga

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

StockNews.com

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

Benzinga

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.